BACHEM HOLDING Current Liabilities

What does BACHEM HOLDING do? Bachem Holding AG generates revenue through the provision of peptide and organic molecule manufacturing services for pharmaceutical and biotechnology clients. The company develops and produces active pharmaceutical ingredients (APIs) and biochemical products, marketing its offerings under the Bachem and Clinalfa brands. Its product portfolio includes fluorescent dyes for FRET analysis and glycosylated peptides designed to manipulate drug properties. The firm serves clients in the pharmaceutical and biotechnology sectors, utilizing production facilities in Switzerland and the United States to support its manufacturing operations. The company's revenue streams are derived from the sale of its branded products, including fluorescent dyes for receptor-ligand interaction studies and glycosylated peptides for drug property modification. These products are targeted at research and development departments within pharmaceutical and biotechnology firms. Bachem Holding AG's manufacturing capabilities for peptides and organic molecules form the core of its business model, with a focus on high-value biochemical solutions for industry clients. Bachem Holding AG's business model centers on technology-based biochemical services, with its primary revenue coming from the sale of APIs and specialized biochemical products. The company operates production facilities in Switzerland and the United States, enabling it to serve global clients in the pharmaceutical and biotechnology industries. Its branded portfolio, including Bachem and Clinalfa, supports the delivery of peptide-based solutions and research tools for drug development and analysis. BACHEM HOLDING is one of the most popular companies on Eulerpool.